紫杉醇联合奈达铂术前辅助治疗局部晚期宫颈癌的有效性及安全性研究  

Efficacy and safety of paclitaxel combined with nedaplatin prior the treatment of locally advanced cervical cancer

作　　者：吴宇翔[1] 时沛[1] Wu Yuxiang;Shi Pei(Department of Oncology,the First Affiliated Hospital of Nanyang Medical College,Nanyang 473058,China)

机构地区：[1]南阳医学高等专科学校第一附属医院肿瘤内科,河南南阳473058

出　　处：《中国实用医刊》2018年第15期114-116,共3页Chinese Journal of Practical Medicine

摘　　要：目的 探讨紫杉醇联合奈达铂术前辅助治疗局部晚期宫颈癌的临床疗效.方法 选取2013年6月至2015年6月南阳医学高等专科学校第一附属医院收治的局部晚期宫颈癌患者140例为研究对象,随机分为对照组和观察组,每组70例,其中对照组给予紫杉醇联合顺铂术前辅助治疗局部晚期宫颈癌,观察组给予紫杉醇联合奈达铂进行辅助治疗,28 d为一疗程,共4个疗程.分析治疗后两组患者的缓解率、生存率、中位生存期、放射相关不良反应及转移复发率.结果 在近期疗效上,两组患者总治疗缓解率比较,差异未见统计学意义（P〉0.05）.但在完全缓解率上,观察组优于对照组（32.86％比20.00％,P〈0.05）;远期疗效上,对照组1、2、3年生存率分别为80.00％、55.71％、32.8％,中位生存期为25.1个月;观察组1、2、3年生存率分别为87.14％、58.57％、48.57％,中位生存期为36.4个月;两组1、2、3年生存率比较差异未见统计学意义（P〉0.05）;3年生存率及中位生存期比较,观察组显著优于对照组（P〈0.05）.观察组转移复发率及不良反应发生率（白细胞减少、骨髓抑制与恶心呕吐发生率）均低于对照组,差异有统计学意义（P〈0.05）.结论 紫杉醇联合奈达铂术前辅助治疗局部晚期宫颈癌,在近远期疗效及相关不良反应方面均具有一定的优势,临床上可以借鉴使用.Objective To investigate the clinical efficacy of paclitaxel combined with nedaplatin prior treatment of locally advanced cervical cancer. Methods A total of 140 patients with locally ad- vanced cervical cancer admitted to the First Affiliated Hospital of Nanyang Medical College from June 2013 to June 2015 were selected as research objects, and they were divided into control group and obser- vation groups randomly, with 70 cases in each group. Patients in control group were given paclitaxel plus cisplatin adjuvant therapy for locally advanced cervical cancer. Patients in observation group were given paclitaxel combined with nedaplatin for adjuvant treatment, with 28 days as a course of treatment, and the treatment included 4 courses. The remission rate, survival rate and median survival time, adverse reactions related to radiation and relapse rate of the two groups were analyzed. Results In terms of short- term curative effect, there was no significant difference in the total remission rate between the two groups （P 〉 0. 05 ）. However, the complete remission rate of observation group was significantly better than that of control group （32. 86% vs. 20.00% , P 〈 0.05）. In terms of the long-term effect, the 1-, 2- and 3-year survival rate of control group was 80.00% , 55.71% , 32.8% , respectively, median survival period was 25. 1 months; the 1-, 2- and 3-year survival rate of observation group was 87. 14% , 58.57% , 48.57% , respectively, and the median survival time was 36.4 months. There was no significant difference in 1- or 2-year survival rate between the two groups （ P 〉 0.05 ）. The 3-year survival rate and median survival time in observation group were significantly better than those in control group （ P 〈 0.05 ）. The incidences of metastasis relapse and adverse reactions （ leukocyte reduction, bone marrow suppression, nausea and vomiting） of observation group were significantly better than those of control group （ P 〈 O. 05 ）. Conclusions Paclitaxel combined with nedaplatin

关 键 词：紫杉醇 奈达铂 顺铂 局部晚期宫颈癌 

分 类 号：R737.33[医药卫生—肿瘤]